Key result
Endovascular thrombectomy did not improve 90-day mRS 0-1 vs medical management and increased symptomatic ICH.
Why the study?
Medium and distal vessel occlusions account for 25-40% of acute ischemic strokes, yet the benefit of endovascular thrombectomy in this population remains contested.
Does endovascular thrombectomy plus medical management improve 90-day functional outcomes compared to medical management alone in patients with primary medium and distal vessel occlusion acute ischemic stroke?
Meta-Analysis (n=1,997)
Yes
Does endovascular thrombectomy plus medical management improve 90-day functional outcomes compared to medical management alone in patients with primary medium and distal vessel occlusion acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
Routine endovascular thrombectomy for medium and distal vessel occlusion stroke provides no 90-day functional benefit over medical management alone while more than doubling the risk of intracranial hemorrhage.
Introduction/Purpose: Medium and distal vessel occlusions (MeVO/DVO) account for 25-40% of acute ischemic strokes, yet the benefit of endovascular thrombectomy (EVT) in this population remains contested. With five randomized trials now reported, we performed an updated meta-analysis of EVT plus medical management versus medical management (MM) alone in MeVO/DVO stroke. Materials/Methods: We searched PubMed, Embase, Cochrane CENTRAL and major stroke conference proceedings through August 2026 for randomized trials comparing EVT with MM alone in primary MeVO/DVO stroke. Odds ratios (OR) with 95% confidence intervals were pooled using Mantel-Haenszel random-effects models; heterogeneity was quantified by I². Efficacy outcomes were 90-day modified Rankin Scale (mRS) 0-1, 0-2 and 0-3. Safety outcomes included 90-day mortality, and symptomatic (sICH) and any intracranial hemorrhage at 24 hours. Results: Five randomized controlled trials enrolling 1,997 patients (990 EVT, 1,007 MM) were included. Median age ranged 68-77 years, median NIHSS 6-10, and middle cerebral artery M2 was the commonest occlusion site (Table). At 90-day follow-up, there was no difference in excellent (mRS 0-1: 41.7% vs 37.7%; OR 1.18, 0.85-1.63; I²=67.4%), good (mRS 0-2: 56.8% vs 55.2%; OR 1.03, 0.76-1.38; I²=59.7%) or fair (mRS 0-3: 72.1% vs 74.8%; OR 0.87, 0.71-1.07; I²=0%) functional outcomes between EVT and MM groups. EVT more than doubled sICH (5.6% vs 2.3%; OR 2.60, 1.59-4.26; I²=0%) and any hemorrhage (28.9% vs 15.2%; OR 2.35, 1.86-2.95; I²=27.5%). Mortality was numerically higher with EVT (9.5% vs 7.3%; OR 1.33, 0.94-1.89) (Figure). Conclusion: Across five randomized trials, EVT for MeVO/DVO stroke conferred no functional benefit at 90 days while more than doubling intracranial hemorrhage, with a nonsignificant trend toward higher mortality. These pooled data do not support routine EVT for MeVO. Individual patient data meta-analysis may reveal subgroups, by occlusion site, thrombolysis eligibility or deficit severity, in whom benefit may persist.
No takes yet. Share an insight, caveat, or question.
Tariq et al. (2026) conducted a meta-analysis in Acute ischemic stroke with primary medium and distal vessel occlusions (MeVO/DVO) (n=1,997). Endovascular thrombectomy plus medical management vs. Medical management alone was evaluated on Excellent functional outcome (90-day modified Rankin Scale 0-1) (OR 1.18, 95% CI 0.85-1.63). Endovascular thrombectomy did not improve 90-day mRS 0-1 vs medical management and increased symptomatic ICH.
Synapse has enriched 10 related papers. Consider them for comparative context: